NVO

Equity

Novo Nordisk A/S

Health Care · Drug Manufacturers - General

$36.66

+36.66 (+0.00%)

Open

N/A

Day Range

$35.85 - $36.95

52W Range

$35.85 - $91.90

Volume

33M

Price History

Key Statistics

Market Cap

N/A

P/E Ratio

N/A

EPS

N/A

Dividend Yield

N/A

P/B Ratio

N/A

Payout Ratio

N/A

ROE

N/A

Debt/Equity

N/A

Latest News

Novo Nordisk Reportedly Warned Over Use of Misleading Claims in Ozempic Ad

MT Newswires 2 hours ago

Is Novo Nordisk (NYSE:NVO) Now Pricing In Too Much Pessimism After Share Price Slump

Simply Wall St. 7 hours ago

Novo Nordisk Deepens Oral GLP 1 Bet With Vivtex Deal And Ireland Spend

Simply Wall St. 13 hours ago

Novo Nordisk Expands Pediatric Reach And Oral Pipeline As Valuation Lags

Simply Wall St. 14 hours ago

Should You Forget Eli Lilly and Buy These Unstoppable Stocks Instead?

Motley Fool 17 hours ago

Peers in Health Care

Symbol Name Price Mkt Cap Div Yield Change
ABBV AbbVie Inc. $233.86 N/A 2.84% +0.00%
CRSP CRISPR Therapeutics AG $58.06 N/A - +0.00%
ACAD ACADIA Pharmaceuticals Inc. $22.50 N/A - +0.00%
AHCO AdaptHealth Corp. $9.40 N/A - +0.00%
A Agilent Technologies, Inc. $119.04 N/A 0.84% +0.00%
ACB Aurora Cannabis Inc. $3.48 N/A - +0.00%
001540.KQ AHN-GOOK PHA $7,870.00 N/A 5.59% +0.00%
ABT Abbott Laboratories $114.12 N/A 2.10% +0.00%

Community Sentiment

Sign in to vote

0% Bullish 0% Neutral 100% Bearish

0 votes

Discussion (0)

Sign in to join the discussion

Loading comments...

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides NovoPen 6 and NovoPen Echo Plus, smart insulin pens; Dose Check, an insulin dose guidance application; and growth hormone pens and injection needles. It operates in Europe, Canada, the United States, Japan, Korea, Oceania, Southeast Asia, Mainland China, Hong Kong and Taiwan, Latin America, the Middle East, and Africa. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

www.novonordisk.com →

🐂 Bull Score

Our proprietary rating measures dividend reliability based on 6 fundamental factors including payout sustainability, financial strength, and cash flow coverage.

F 25/100

Very Risky

Bull Score

~ Growing dividend (8 years) 10/25
+ Excellent profit margin (33%) 15/15
Limited data — score may change as more metrics become available

Dividend Safety

Assessment based on payout ratio, debt levels, profit margins, and dividend growth track record.

70

Safe

Based on 4 fundamental factors

+ 8 years of growth
+ Strong profit margins (33%)

Analysis Tools

Sign in for analysis tools

Share